Lexeo Therapeutics (LXEO) – Analysts’ Recent Ratings Changes

Lexeo Therapeutics (NASDAQ: LXEO) has recently received a number of price target changes and ratings updates:

• 5/29/2026 – Lexeo Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/16/2026 – Lexeo Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/15/2026 – Lexeo Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/11/2026 – Lexeo Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $17.00 price target on the stock.
• 5/2/2026 – Lexeo Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/1/2026 – Lexeo Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/17/2026 – Lexeo Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the transaction, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at approximately $1,935,203.14. This trade represents a 13.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 59,644 shares of company stock valued at $336,462. 5.30% of the stock is currently owned by company insiders.

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.